Tobam Decreases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Tobam lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 18.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,241 shares of the medical device company's stock after selling 10,493 shares during the period. DexCom makes up 1.4% of Tobam's portfolio, making the stock its 24th biggest position. Tobam's holdings in DexCom were worth $3,158,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of DXCM. Brighton Jones LLC lifted its stake in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after acquiring an additional 11,946 shares in the last quarter. Stratos Wealth Partners LTD. bought a new stake in DexCom in the 4th quarter valued at $201,000. Empowered Funds LLC raised its stake in DexCom by 37.0% in the 4th quarter. Empowered Funds LLC now owns 8,010 shares of the medical device company's stock valued at $623,000 after acquiring an additional 2,163 shares during the period. Kestra Private Wealth Services LLC grew its holdings in DexCom by 47.8% in the 4th quarter. Kestra Private Wealth Services LLC now owns 11,047 shares of the medical device company's stock valued at $859,000 after buying an additional 3,574 shares in the last quarter. Finally, Essex Financial Services Inc. increased its position in DexCom by 3.3% during the 4th quarter. Essex Financial Services Inc. now owns 9,617 shares of the medical device company's stock worth $748,000 after buying an additional 303 shares during the period. Institutional investors own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

DXCM has been the topic of several analyst reports. Wall Street Zen raised DexCom from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Robert W. Baird decreased their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Piper Sandler decreased their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Finally, Barclays upped their price target on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $98.32.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 6,184 shares of the stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the transaction, the executive vice president now owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00. Following the transaction, the executive vice president now directly owns 95,602 shares of the company's stock, valued at $8,057,336.56. The trade was a 9.47% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,536 shares of company stock valued at $1,393,876. Company insiders own 0.32% of the company's stock.

DexCom Price Performance

NASDAQ DXCM traded down $0.86 during trading hours on Friday, hitting $81.99. 2,904,075 shares of the company's stock traded hands, compared to its average volume of 4,350,358. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $117.91. The company has a market capitalization of $32.15 billion, a PE ratio of 57.34, a PEG ratio of 2.30 and a beta of 1.46. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm's 50-day moving average is $78.50 and its 200-day moving average is $79.33.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same period last year, the company earned $0.32 EPS. The business's quarterly revenue was up 12.5% on a year-over-year basis. Equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.